Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS101 vs Dupixent in Moderate-to-Severe Atopic Dermatitis
NCT07386743Phase 3Recruiting
- Sponsor
- Genscript ProBio
- Start
- Jan 2026
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of GS101 in atopic dermatitis (AD), sponsored by Genscript ProBio. Started Jan 2026; status: recruiting.
02
Drugs
GS101
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07386743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07386743.